547
INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASES IN HISPANICS IN THE UNITED STATES, 2011-2020
Date
May 19, 2024
Tracks
Related Products
CHRONOLOGICAL AGE INFLUENCES TREATMENT DECISION IN INFLAMMATORY BOWEL DISEASE
BACKGROUND: Despite older adults making up roughly one quarter of patients with inflammatory bowel disease (IBD) in the United States, they are an understudied population…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
DISEASE CLEARANCE AFTER 16 WEEKS OF TREATMENT WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM THE VERDICT TRIAL
BACKGROUND: Disease clearance in ulcerative colitis (UC) is defined as concurrent achievement of clinical, endoscopic, and histologic remission…
TRAVEL TIME TO TREATING CENTER, BUT NOT RACE OR ETHNICITY IS ASSOCIATED WITH DIAGNOSTIC DELAY IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
BACKGROUND: Perianal fistulizing complications (PFC) of Crohn’s disease (CD) are highly morbid and difficult to treat. Despite the advent of biologic medications, antibiotics remain a mainstay of PFC treatment…